Double bottom with a potential double‑up The price dropped sharply after the company projected a revenue decline for 2026.
A perfect double bottom has formed around $43, and now it’s just waiting for a breakout above the neckline to project a target toward $81.5.
Someone more famous than me once said: “Be greedy when others are fearful,
Novo Nordisk A/S
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.47 USD
15.49 B USD
46.74 B USD
3.37 B
About Novo Nordisk A/S Class B
Sector
Industry
CEO
Maziar Mike Doustdar
Website
Headquarters
Bagsværd
Founded
1923
IPO date
May 17, 1974
Identifiers
3
ISIN US6701002056
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
NVO I like it. NVO
Health care sector.
Looks like a decent place for me to add some NYSE:NVO to my portfolio.
There is a volume shelf here. If it can hold the zone blue line then as MFI grows should lift off this area.
It could break through this floor and goto $30 area. For me would be an even better spot
Novo Nordisk about to finish accumulation range?As the title says. Looks like NYSE:NVO is finishing up an relative small accumulation range. Question is whether the spring-test is done here or not. Sometimes there's a big push and retrace to create a test. Sometimes something that resembles current PA can be enough.
Let's see how it develops.
RECAP - Stock Plunges on Aggressive 2026 Guidance Novo Nordisk Faces a Pivotal Year: Stock Plunges on Aggressive 2026 Guidance - A Buying Opportunity or a Red Flag?
The pharmaceutical sector was jolted on Tuesday as Novo Nordisk A/S (NYSE: NVO), the Danish titan behind blockbuster GLP-1 drugs Ozempic and Wegovy, saw its share price tumble nearly 15
NVO Alert: Quick Downside Opportunity📉 NVO Weekly Trade (Speculative Bearish)
Direction: Short / Put
Instrument: NVO $62 Put
Expiry: Jan 30, 2026 (Friday)
Entry Zone: $1.65 – $1.72
🎯 Targets
Target 1: $2.06 (+25%) → scale 50%
Target 2: $2.64 (+60%+) → use trailing stop
Risk: Stop loss: $1.29
Hard exit: NVO above $64.16
Notes /
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
XS323295972
Novo Nordisk Finance (Netherlands) BV 4.0% 20-NOV-2045Yield to maturity
4.19%
Maturity date
Nov 20, 2045
N
XS323295590
Novo Nordisk Finance (Netherlands) BV 3.625% 20-FEB-2038Yield to maturity
3.68%
Maturity date
Feb 20, 2038
N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037Yield to maturity
3.66%
Maturity date
May 27, 2037
N
XS323294453
Novo Nordisk Finance (Netherlands) BV 3.375% 20-FEB-2035Yield to maturity
3.44%
Maturity date
Feb 20, 2035
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034Yield to maturity
3.33%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033Yield to maturity
3.16%
Maturity date
May 27, 2033
N
XS323293716
Novo Nordisk Finance (Netherlands) BV 3.0% 20-FEB-2032Yield to maturity
3.04%
Maturity date
Feb 20, 2032
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031Yield to maturity
2.88%
Maturity date
Jan 21, 2031
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030Yield to maturity
2.87%
Maturity date
Aug 27, 2030
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030Yield to maturity
2.65%
Maturity date
Mar 31, 2030
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028Yield to maturity
2.61%
Maturity date
May 27, 2028
See all NVO bonds









